Company attributes
Other attributes
What is Rubius Therapeutics?
Rubius Therapeutics is a biotechnology company using stem cells to develop red blood cell cellular therapies that is headquartered in Cambridge, Massachusetts and was founded in 2013 by Avak Kahvejian.
The company is primarily interested in creating life-changing, allogenic cellular therapies for patients with severe diseases. They have developed a proprietary RED PLATFORM to generate red blood cells and genetically engineer them into a new class of cellular medicines. The platform harnesses properties of red blood cells and the genetic engineering to deliver their promise of cellular therapy as a solution to diseases and treatments of those diseases.
The company expresses biotherapeutic proteins within or on their cell surface to create selective, potent, allogenic cellular medicines aimed at treating a range of diseases. This can potentially be used to kill tumors in cancer as well as regulate the immune system in order to treat autoimmune diseases. The leveraging of distinct therapeutic modalities includes immune system activation and tolerance induction.
On December 9, 2015 Rubius Therapeutics announced completing their series A funding round with $25 million in funding from Flagship Pioneering.
On June 21, 2017 Rubius Therapeutics completed their series B funding round with $120 million in funding from Flagship Pioneering.
On March 1, 2018 Rubius Therapeutics closed their series C funding round with $100 million in funding from Flagship Pioneering and 26 other participating investors.
